BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 2019;17:319-30. [DOI: 10.1080/14779072.2019.1598263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ajam T, Cumpian TL, Tilkens BL, Jahangir IA, Frost J, Ceretto C, Jahangir A. Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Expert Rev Clin Pharmacol 2020;13:1309-27. [PMID: 33107345 DOI: 10.1080/17512433.2020.1842191] [Reference Citation Analysis]
2 Grimaldi G, Ancona D, Tricarico D, Stella P, Procacci C, Germinario A, Bavaro V, Montanaro V, Delle Donne A. Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. Pharmaceutics 2021;13:252. [PMID: 33670408 DOI: 10.3390/pharmaceutics13020252] [Reference Citation Analysis]
3 Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus. Ann Pharmacother 2021;55:839-45. [DOI: 10.1177/1060028020975111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Biembengut ÍV, de Souza TACB. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Mem Inst Oswaldo Cruz 2020;115:e200179. [PMID: 32490889 DOI: 10.1590/0074-02760200179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]